Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276328 | 0.82 | RIPK1 (0.34) | RIPK1SMN1; SMN2 | |
| SCHEMBL3276191 | 0.80 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL3276664 | 0.71 | USP2 (0.39) | RIPK1SMN1; SMN2 | |
| SCHEMBL9903878 | 0.57 | USP2 (0.41) | SMN1; SMN2 | |
| SCHEMBL23997014 | 0.56 | HSP90AA1 (0.51) | SMN1; SMN2 | |
| SCHEMBL3280126 | 0.55 | RIPK1 (0.42) | RIPK1 | |
| SCHEMBL28466622 | 0.55 | AHR (0.41) | RIPK1SMN1; SMN2 | |
| SCHEMBL23798617 | 0.55 | CNR2 (0.32) | SMN1; SMN2 | |
| SCHEMBL25261807 | 0.55 | HDAC6 (0.34) | — | |
| SCHEMBL21800547 | 0.54 | RIPK1 (0.54) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | RIPK1 4189/4885SMN1; SMN2 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.